Middle East & Africa Left Ventricular Assist Device Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Type of Flow (Pulsatile Flow and Non-Pulsatile Flow), Design (Implantable Ventricular Assist Devices and Transcutaneous Ventricular Assis

Middle East & Africa Left Ventricular Assist Device Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Type of Flow (Pulsatile Flow and Non-Pulsatile Flow), Design (Implantable Ventricular Assist Devices and Transcutaneous Ventricular Assist Devices), and Application (Bridge to Transplantation, Destination Therapy, Bridge to Recovery, and Bridge to Candidacy)

The Middle East & Africa left ventricular assist device market in is expected to grow from US$ 70.56 million in 2022 to US$ 88.86 million by 2028. It is estimated to register a CAGR of 3.9% from 2022 to 2028.

Increasing Use of Artificial Intelligence and Machine Learning in LVAD is fueling the growth of Middle East & Africa Left Ventricular Assist Device Market

The increased incidence of complications and adverse events associated with LVAD encourages manufacturers to develop innovative technologies and integrate new technologies into the devices. In several cases, patients with LVAD devices experience right ventricle failure leading to blood buildup in veins and swelling. To reduce the failure, manufacturers have integrated artificial intelligence (AI) with LVAD to monitor the right ventricle. With this, any change in the right ventricle activity and function will be reported to the healthcare professional, reducing the chances of right ventricle failures and complications. Furthermore, the increased use of machine learning (ML) for developing risk scores indicating heart failure mortality provides an edge over conventional methods. Additionally, telemetry data analysis from wearable devices helps predict heart failure hospitalizations. Therefore, the use of artificial intelligence and machine learning algorithms helps develop a risk prediction model based on right ventricle functions in end-stage heart failure patients with LVAD. The risk stratification for right ventricle failure is one of the significant factors that help determine patients’ survival. Therefore, the integration of artificial intelligence and machine learning in LVADs is likely to emerge as a key trend in the left ventricle assist device market in the Middle East & Africa during the forecast period.

Middle East & Africa Left Ventricular Assist Device Market Overview

The Middle East & Africa left ventricular assist devices market has been segmented into the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share during the forecast period. The market in South Africa is expected to grow at the highest CAGR during the forecast period. The market growth in the Middle East & Africa is attributed to factors such as a rise in the prevalence of cardiovascular disorder cases, an increase in the incidence of heart failure, the long waiting list for heart transplantation, and the development of healthcare infrastructure. Additionally, an increase in medical tourism in the region, followed by a surge in disposable income, is expected to create a demand for LVADs in the coming years. Moreover, rising investments in the healthcare sector from several private institutions and increasing collaboration of hospitals with developed regions are further expected to boost the Middle East & Africa left ventricular assist device market during the forecast period.

Middle East & Africa Left Ventricular Assist Device Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Left Ventricular Assist Device Market Segmentation

The Middle East & Africa left ventricular assist device market is segmented into type of flow, design, application, and country.

Based on type of flow, the Middle East & Africa left ventricular assist device market is segmented into non-pulsatile and pulsatile flow . The non-pulsatile segment registered the largest market share in 2022.

Based on design, the Middle East & Africa left ventricular assist device market is bifurcated into implantable ventricular assist devices and transcutaneous ventricular assist devices . The implantable ventricular assist devices segment registered the largest market share in 2022.

Based on application, the Middle East & Africa left ventricular assist device market is segmented into destination therapy, bridge to transplantation, bridge to candidacy, and bridge to recovery . The destination therapy segment registered the largest market share in 2022

The Middle East & Africa left ventricular assist device market, by country, is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

ABIOMED Inc; Abbott Laboratories; Medtronic Plc; LivaNova Plc; and Evaheart Inc are the leading companies operating in the Middle East & Africa left ventricular assist devices market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa left ventricular assist device market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa left ventricular assist device market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the left ventricular assist device market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution